Julius Knowles Biography and Net Worth

Director of Keros Therapeutics

Julius Knowles has served as a member of our board of directors since April 2016. Mr. Knowles is a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. Prior to Partners, Mr. Knowles was the Chief Executive Officer of X-BODY BioSciences (acquired by Juno Therapeutics). Previously, Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research, President of Novalar Pharmaceuticals, Vice President of Business Development of Novacea, (acquired by Transcept Pharmaceuticals), Vice President of Business Development of SGX Pharmaceutical and Director of Research and Development Planning at Vertex Pharmaceuticals. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley.

How do I contact Julius Knowles?: The corporate mailing address for Mr. Knowles and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected]. Learn More on Julius Knowles' contact information.
Has Julius Knowles been buying or selling shares of Keros Therapeutics?: Julius Knowles has not been actively trading shares of Keros Therapeutics during the past quarter. Most recently, Julius Knowles sold 4,034 shares of the business's stock in a transaction on Wednesday, January 5th. The shares were sold at an average price of $58.25, for a transaction totalling $234,980.50. Learn More on Julius Knowles' trading history.
Who are Keros Therapeutics' active insiders?: Keros Therapeutics' insider roster includes Julius Knowles (Director), and Jennifer Lachey (Insider). Learn More on Keros Therapeutics' active insiders.
Are insiders buying or selling shares of Keros Therapeutics?: During the last year, insiders at the sold shares 1 times. They sold a total of 250,000 shares worth more than $11,002,500.00. The most recent insider tranaction occured on August, 13th when Director Carl L Gordon sold 250,000 shares worth more than $11,002,500.00. Insiders at Keros Therapeutics own 22.9% of the company. Learn More about insider trades at Keros Therapeutics.
Information on this page was last updated on 8/13/2024.

Julius Knowles Insider Trading History at Keros Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
1/5/2022	Sell	4,034	$58.25	$234,980.50
1/3/2022	Sell	23,555	$58.01	$1,366,425.55
11/3/2021	Sell	15,967	$41.95	$669,815.65
11/1/2021	Sell	23,803	$42.15	$1,003,296.45
10/20/2021	Sell	4,082	$38.24	$156,095.68
10/18/2021	Sell	13,786	$37.70	$519,732.20
10/14/2021	Sell	4,383	$40.13	$175,889.79
10/4/2021	Sell	3,746	$40.06	$150,064.76
10/1/2021	Sell	6,323	$40.16	$253,931.68
9/27/2021	Sell	95,302	$41.17	$3,923,583.34
7/1/2021	Sell	23,834	$41.28	$983,867.52
6/7/2021	Sell	12,796	$49.89	$638,392.44
6/3/2021	Sell	7,895	$47.97	$378,723.15
6/1/2021	Sell	8,812	$52.51	$462,718.12
5/3/2021	Sell	44,816	$57.48	$2,576,023.68
4/5/2021	Sell	27,151	$60.07	$1,630,960.57
4/1/2021	Sell	11,202	$58.89	$659,685.78
3/3/2021	Sell	12,327	$57.36	$707,076.72
3/1/2021	Sell	12,979	$63.09	$818,845.11
2/18/2021	Sell	28,617	$60.87	$1,741,916.79
2/11/2021	Sell	11,561	$64.82	$749,384.02

Julius Knowles Buying and Selling Activity at Keros Therapeutics

Keros Therapeutics Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $17.03

$16.62

$17.64

50 Day Range

MA: $54.97

$16.92

$70.00

2 Week Range

Now: $17.03

$15.67

$73.00

Volume

1,468,811 shs

Average Volume

487,363 shs

Market Capitalization

$689.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol